Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Research & Development (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Research & Development for 2 consecutive years, with $496000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Research & Development rose 687.3% year-over-year to $496000.0, compared with a TTM value of $1.2 million through Jun 2025, changed N/A, and an annual FY2024 reading of $414000.0, up 404.88% over the prior year.
  • Research & Development was $496000.0 for Q2 2025 at Kairos Pharma, up from $493000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $496000.0 in Q2 2025 and bottomed at $14000.0 in Q3 2024.